Arthneeti
All Q2 FY26 results →
M.

Medline Inc.

Q2 FY26Health Care Equipment and Supplies

Medline Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹37
Market cap₹48.3K Cr
P/E31.7
Updated29 May 2026
Read3 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

- Raised full-year 2026 organic sales growth guidance to 8.5%–9.5%, up from 8%–9%, reflecting strong Q1 performance. - Raised full-year 2026 organic sales growth guidance to 8.5% - 9.5%, up from previous 8% - 9% range, driven by strong Q1 sales and steady healthcare utilization.

From Medline Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • Raised full-year 2026 organic sales growth guidance to 8.5%–9.5%, up from 8%–9%, reflecting strong Q1 performance.
  • Strong momentum driven by new customer signings ($2.4 billion in 2025) and solid same-store sales growth.
  • Supply Chain Solutions delivered over 15% top-line growth in Q1, fueled by same-store growth and new customer implementations.
  • Expect some moderation in same-store sales growth in H2 2026 due to market uncertainties (ACA, ODBA).
  • U.S. non-acute business growing faster than acute, with continued share gains and robust demand across post-acute, surgery centers, and physician offices.
  • Long-term pipeline remains robust; about 50% of top 100 US health systems remain untapped, offering significant growth opportunity.

2 more points from Medline Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Medline Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Continued investments in sales to drive top-line growth.
  • Investments in operations to maintain best-in-industry service levels.
  • IT investments focusing on cybersecurity, AI capabilities, and warehouse management.
  • Building out service technician capacity, particularly in Canadian market expansion.

2 more points from Medline Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Medline Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The company reported a strong start to the year with $2.4 billion in total new customer signings for 2025.
  • Implementation ramp of these signings is underway, with about 25% revenue realization expected in 2025, 65% in 2026, and the remainder in 2027.
  • New prime vendor signings are progressing well, on track to achieve a goal of $1 billion in new prime vendor signings for the year.
  • The pipeline for new customer wins is described as very robust, with significant opportunities in healthcare consolidation.

Continue your research

Others in Health Care Equipment and Supplies this season

  • Insulet Corporation (Q2 FY26)

    Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24

  • Globus Medical, Inc. (Q2 FY26)

    Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.

  • Align Technology, Inc. (Q2 FY26)

    Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap

  • Solventum Corporation (Q2 FY26)

    Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporationvs Medtronic plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Medline Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Medline Inc. Q2 FY26 results?

- Raised full-year 2026 organic sales growth guidance to 8.5%–9.5%, up from 8%–9%, reflecting strong Q1 performance. - Raised full-year 2026 organic sales growth guidance to 8.5% - 9.5%, up from previous 8% - 9% range, driven by strong Q1 sales and steady healthcare utilization.

What is Medline Inc. share price analysis?

Medline Inc. currently shows a below-average growth signal. The stock trades at a P/E of 31.7 with a market cap of $48,344. Investors should review the full earnings analysis for detailed insights.

Is Medline Inc. planning capital expenditure?

- Continued investments in sales to drive top-line growth.

Keep Medline Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.